

# MultiScreen Filter Plates for PAMPA

## Evaluation of the reproducibility of Parallel Artificial Membrane Permeation Assays (PAMPA)

**Daniel Schmidt and John Lynch, PhD**

### Abstract


The reproducibility and precision of an automation compatible, high throughput method for predicting passive, intestinal absorption was assessed. The Parallel Artificial Membrane Permeation Assay (PAMPA) has been previously reported<sup>1, 2</sup>, and is based on the use of a 96-well membrane filter based plate. The permeability of six drugs (propranolol, methotrexate, warfarin, carbamazepine, furosemide, and testosterone) was measured on different days using three different lots of plates. In addition, several protocol variations (volume of lipid solution, time between lipid application and drug addition, etc.) were tested to simulate the analytical variability that might be encountered from lab to lab and from operator to operator. The results presented in this Application Note demonstrate that under typical conditions, the PAMPA assay is robust and generates reproducible data. Small protocol variations can have an effect on the apparent permeability rates of some drugs, but in general, the rank order by  $\log P_e$  (log of the effective permeability) of the compounds is unaffected. As would be expected, variation in the lipid content can significantly alter  $\log P_e$  results for some compounds. This observation supports the use of the PAMPA method to measure permeability through lipid formulations that simulate different membrane types (e.g., blood-brain barrier, mitochondrial membrane, etc.).

### Introduction

PAMPA is a non-cell based assay designed to predict passive, transcellular permeability of drugs in early drug discovery. The assay is carried out in a 96-well, MultiScreen®-IP PAMPA filter plate. The ability of compounds to diffuse from a donor compartment, through a PVDF membrane filter pretreated with a lipid-containing organic solvent, into an acceptor compartment is evaluated.



After the artificial membrane has been applied to the PVDF membrane filter in the filter plate (known as the Donor plate), the 96-well Donor plate is immediately filled with buffer solutions containing the compounds to be tested. The Donor plate is then placed upon a 96-well Acceptor plate filled with sufficient buffer to ensure liquid contact between the buffer in the Acceptor plate and the PVDF membrane filter. The Acceptor plate should be made of PTFE (recommended; Millipore® Cat. No. MSSACCEPTOR) or an equivalent, low-binding plastic. The Acceptor plate is not supplied with the filter plate. The Donor and Acceptor plates are incubated together for 2–16 hours after which the Donor plate is removed from the Acceptor plate (See **Figure 1**). The 96 wells in the Acceptor plate can be directly analyzed by LC/MS or transferred to a UV compatible 96-well plate and analyzed immediately in a UV/Vis spectrophotometer. The PAMPA method can also be used to determine the effect of pH on compound permeability by adjusting the pH of the solutions used in the analysis. These plates are particularly recommended for use in pre-ADME or Discovery programs requiring compound rank ordering or profiling.



**Figure 1:** Individual Donor/Acceptor Well Assembly Before and After Incubation

## General Protocol Considerations

In addition to the MultiScreen®-IP PAMPA (Donor) filter plate and an Acceptor plate (**MSSACCEPTOR** or equivalent), a UV/Vis spectrophotometer capable of analyzing 96-well plates and UV compatible, 96-well sample plates are also required to run the assay. Sonication of the lipid/organic solvent solution is recommended to ensure complete dissolution of the lipid prior to membrane application.

## Experimental Materials

Methotrexate (**Cat. No. M7824**), propranolol (**Cat. No. P-0884**), warfarin (**Cat. No. A-2250**), carbamazepine (**Cat. No. C-8981**), furosemide (**Cat. No. F-4381**), testosterone (**Cat. No. T-1500**), phenazopyridine (**Cat. No. PHR3220**), L- $\alpha$ -phosphatidylcholine "lecithin" (**Cat. No. P-3556**) n-dodecane (**Cat. No. D-4259**), dimethyl sulfoxide (**Cat. No. D-8779**) and phosphate buffered saline (PBS) (**Cat. No. P-3813**) were purchased, along with MultiScreen®-IP PAMPA assay plates (**Cat. No. MAIPN0B0**) and PTFE Acceptor plates (**Cat. No. MSSACCEPTOR**). A SpectraMax® Plus microtiter plate reader, SoftMax® Pro and a UV compatible quartz plate (part no. R8024) were purchased from Molecular Devices (Sunnyvale, CA). A sonicator/cell disruptor was purchased from Branson Ultrasonics (Mumbai, India). Polypropylene reagent reservoirs (**Cat. No. 175-RBAS-000**) were purchased from ELKay Laboratory Consumables (Shrewsbury, MA). A Finnpiptette® electronic pipettor (**Cat. No. 21377232**) was purchased from ThermoLabsystems (Helsinki, Finland). A BioHit™ 8 channel electronic pipettor and polypropylene tips (**Cat. No. W67-710-800** and **W16-160045**) were purchased from Vanguard International (Neptune, NJ).

## Methods

The following protocol was used to determine log  $P_e$  for methotrexate, propranolol, warfarin, carbamazepine, furosemide and testosterone.

- Prepare a 1% solution (w/v) of lecithin in dodecane (~500  $\mu$ L/ plate) and sonicate the mixture to ensure complete dissolution.
- Carefully pipette 5  $\mu$ L of the lecithin/dodecane mixture into each Donor plate well, avoiding pipette tip contact with the membrane. Note: use polypropylene reservoir.
- Immediately after the application of the artificial membrane, add 150  $\mu$ L of drug-containing donor solutions (drugs dissolved in 5% DMSO, PBS) to each well of the Donor plate (in the experiments described in this Application Note, the testosterone donor concentration was 100  $\mu$ M. All other drugs were added at a concentration of 500  $\mu$ M).
- Add 300  $\mu$ L of buffer (5% DMSO in PBS, pH 7.4) to each well of the PTFE Acceptor plate (**MSSACCEPTOR**).
- Place the drug-filled Donor plate into the Acceptor plate, making sure the underside of the membrane is in contact with the buffer.
- Replace plate lid and incubate at room temperature for 16 hours. Note: place the assembled plate into a sealed container with wet paper towels to avoid evaporation.
- After incubation, measure UV/Vis absorption from 250 to 500 nm for 100  $\mu$ L/well of the donor solution and 250  $\mu$ L/well of the acceptor solution.
- Prepare drug solutions at the theoretical equilibrium concentration (i.e., the resulting concentration if the donor and acceptor solutions were simply combined) and measure UV/Vis absorption from 250 to 500 nm for 250  $\mu$ L/well of each.
- Calculate log  $P_e$  using the equation below.

## Equations

Log  $P_e$  can be calculated from the following equation as reported by Faller *et al*<sup>3</sup> and Sugano *et al*<sup>4</sup>

$$\log P_e = \log \left\{ C^* - 1n \left( 1 - \frac{[\text{drug}]_{\text{acceptor}}}{[\text{drug}]_{\text{equilibrium}}} \right) \right\}$$

$$\text{where } C = \left( \frac{V_D * V_A}{(V_D + V_A) \text{ Area} * \text{Time}} \right)$$


## Drug Standard Curves

Standard curves were prepared to determine limits of quantification (LOQ) for each drug when using UV/Vis spectroscopy as the detection method. The LOQ is defined as the concentration of compound whose absorbance (optical density, OD) is five times greater than the standard deviation of the background (noise absorbance). Two-fold serial dilutions starting at 100  $\mu\text{M}$  of each drug were made in 5% DMSO/PBS. UV/Vis absorbance for each dilution was measured across 250–500 nm in 10 nm


steps using the SpectraMax® Plus plate reader and quartz sample plate. Peak maximum and area under the curve data were then plotted for each drug (See **Figures 2a–2f**). **Table 1** compares the Limit of Quantification to the typical concentration found in the Acceptor plate. UV/Vis absorbance detection works for all the drugs in the study except for methotrexate, since the LOQ is almost 4 times higher than the typical acceptor concentration.

**Table 1:** UV/Vis Limits of Quantification (LOQ)


| Drug          | LOQ Concentration  | Typical Acceptor Concentration After Incubation |
|---------------|--------------------|-------------------------------------------------|
| Propranolol   | 5.0 $\mu\text{M}$  | 110.2 $\mu\text{M}$                             |
| Methotrexate  | 1.36 $\mu\text{M}$ | 0.4 $\mu\text{M}$                               |
| Warfarin      | 2.89 $\mu\text{M}$ | 20.0 $\mu\text{M}$                              |
| Carbamazepine | 4.51 $\mu\text{M}$ | 87.7 $\mu\text{M}$                              |
| Furosemide    | 1.6 $\mu\text{M}$  | 3.2 $\mu\text{M}$                               |
| Testosterone  | 0.91 $\mu\text{M}$ | 23.5 $\mu\text{M}$                              |




**Figure 2a:** Propranolol Standard Curve



**Figure 2b:** Warfarin Standard Curve



**Figure 2c:** Methotrexate Standard Curve



**Figure 2d:** Carbamazepine Standard Curve




Figure 2e: Furosemide Standard Curve




Figure 2f: Testosterone Standard Curve

## Results

### Reproducibility

To assess the analytical variability (precision) within a plate, the permeability of the six drugs listed in **Table 2** was measured in a single 96-well plate. Each value in **Table 2** is the average log  $P_e$  calculated from 16 readings (wells) per drug plus or minus the standard deviation.

The six drugs listed in **Table 3** were assayed for permeability using six different plates over two days to measure plate-to-plate reproducibility. Each Log  $P_e$  value in the table is the average of 16 wells per drug for each plate plus or minus the standard deviation.

To determine the assay reproducibility from day to day, the six drugs were assayed for permeability on six different days, in three different plates per day using 16 wells per plate. These results (averages and standard deviations) are presented in **Table 4**.

Three different lots of membrane were tested to determine (membrane) lot-to-lot reproducibility. All assays were performed using the standard protocol described in the methods section and the results are presented in **Table 5**. Each value in the table is the average of 96 replicates (16 replicates/plate from 6 plates of each lot).

**Table 2:** Well-to-Well Reproducibility

| (n=16)            |             |               |            |            |              |  |
|-------------------|-------------|---------------|------------|------------|--------------|--|
| Average Log $P_e$ |             |               |            |            |              |  |
| Testosterone      | Propranolol | Carbamazepine | Warfarin   | Furosemide | Methotrexate |  |
| -4.8 ± 0.1        | -5.0 ± 0.1  | -5.2 ± 0.0    | -6.0 ± 0.0 | -6.5 ± 0.1 | -7.2 ± 0.1   |  |

**Table 3:** Plate-to-Plate Reproducibility

| (n=16)     |       |                   |             |               |            |            |              |
|------------|-------|-------------------|-------------|---------------|------------|------------|--------------|
|            |       | Average Log $P_e$ |             |               |            |            |              |
| Day        | Plate | Testosterone      | Propranolol | Carbamazepine | Warfarin   | Furosemide | Methotrexate |
| 1          | 1     | -4.9 ± 0.0        | -5.0 ± 0.0  | -5.2 ± 0.1    | -6.0 ± 0.0 | -6.8 ± 0.0 | -7.7 ± 0.2   |
|            | 2     | -4.9 ± 0.1        | -5.0 ± 0.0  | -5.2 ± 0.0    | -6.0 ± 0.0 | -6.8 ± 0.1 | -7.7 ± 0.3   |
|            | 3     | -4.9 ± 0.1        | -5.0 ± 0.0  | -5.2 ± 0.0    | -6.0 ± 0.0 | -6.9 ± 0.1 | -7.8 ± 0.2   |
| 2          | 1     | -4.9 ± 0.1        | -5.0 ± 0.0  | -5.2 ± 0.0    | -6.0 ± 0.0 | -6.8 ± 0.1 | -7.9 ± 0.3   |
|            | 2     | -4.9 ± 0.0        | -5.0 ± 0.0  | -5.2 ± 0.0    | -6.0 ± 0.0 | -6.8 ± 0.1 | -7.9 ± 0.2   |
|            | 3     | -4.9 ± 0.0        | -5.0 ± 0.0  | -5.2 ± 0.0    | -6.0 ± 0.0 | -6.8 ± 0.1 | -7.9 ± 0.3   |
| Total Ave. |       | -4.9 ± 0.0        | -5.0 ± 0.0  | -5.2 ± 0.0    | -6.0 ± 0.0 | -6.8 ± 0.0 | -7.8 ± 0.1   |

**Table 4: Day-to-Day Reproducibility**

| (n=48)            |                            |                  |                  |                  |                  |                  |
|-------------------|----------------------------|------------------|------------------|------------------|------------------|------------------|
| Day               | Average Log P <sub>e</sub> |                  |                  |                  |                  |                  |
|                   | Testosterone               | Propranolol      | Carbamazepine    | Warfarin         | Furosemide       | Methotrexate     |
| 1                 | -4.9 ±0.1                  | -5.0 ±0.0        | -5.2 ±0.0        | -6.0 ±0.0        | -6.7 ±0.2        | -7.7 ±0.5        |
| 2                 | -4.9 ±0.1                  | -5.0 ±0.0        | -5.2 ±0.1        | -6.0 ±0.0        | -6.8 ±0.1        | -7.7 ±0.3        |
| 3                 | -4.9 ±0.0                  | -5.0 ±0.0        | -5.2 ±0.0        | -6.0 ±0.0        | -6.8 ±0.1        | -7.9 ±0.3        |
| 4                 | -4.9 ±0.1                  | -5.0 ±0.0        | -5.2 ±0.0        | -6.0 ±0.0        | -6.8 ±0.0        | -7.8 ±0.3        |
| 5                 | -4.9 ±0.1                  | -5.0 ±0.0        | -5.2 ±0.0        | -6.0 ±0.0        | -6.7 ±0.0        | -7.8 ±0.2        |
| 6                 | -4.9 ±0.0                  | -5.1 ±0.0        | -5.3 ±0.0        | -6.0 ±0.0        | -6.8 ±0.0        | -8.4 ±0.4        |
| <b>Total Ave.</b> | <b>-4.9 ±0.1</b>           | <b>-5.0 ±0.0</b> | <b>-5.2 ±0.0</b> | <b>-6.0 ±0.0</b> | <b>-6.8 ±0.1</b> | <b>-7.9 ±0.4</b> |

**Table 5: Lot-to-Lot Reproducibility**

| (n=96)            |                            |                  |                  |                  |                  |                  |
|-------------------|----------------------------|------------------|------------------|------------------|------------------|------------------|
| Day               | Average Log P <sub>e</sub> |                  |                  |                  |                  |                  |
|                   | Testosterone               | Propranolol      | Carbamazepine    | Warfarin         | Furosemide       | Methotrexate     |
| 1                 | -4.9 ±0.1                  | -5.0 ±0.0        | -5.2 ±0.0        | -6.0 ±0.0        | -6.7 ±0.1        | -7.8 ±0.4        |
| 2                 | -4.9 ±0.1                  | -5.0 ±0.0        | -5.2 ±0.1        | -6.0 ±0.0        | -6.8 ±0.1        | -7.9 ±0.4        |
| 3                 | -4.8 ±0.0                  | -5.0 ±0.0        | -5.2 ±0.0        | -6.0 ±0.0        | -6.8 ±0.1        | -7.9 ±0.4        |
| <b>Total Ave.</b> | <b>-4.9 ±0.1</b>           | <b>-5.0 ±0.0</b> | <b>-5.2 ±0.0</b> | <b>-6.0 ±0.0</b> | <b>-6.8 ±0.1</b> | <b>-7.9 ±0.4</b> |

## Effects of Protocol Variability

Summarized in **Table 6** and **Table 7** are the log P<sub>e</sub> results obtained using slightly modified protocols. These experiments were conducted to determine the impact of minor protocol changes (especially lecithin concentration and applied volume) on assay results. The last four rows of **Table 6** show the impact of a time delay between the addition of the lecithin solution and the addition of the drug solutions. The average and

standard deviation for the standard protocol include data from at least 3 plate lots, 6 different days and 3 plates with 16 wells for each drug per plate (i.e., at least 1728 assays). For each of the protocol changes, one plate was evaluated with 16 wells for each drug.

Summarized in **Table 7** are the results of varying the concentration of lecithin on the permeability of phenazopyridine. Each value in the table is the average of 6 replicates for each filter treatment.

**Table 6: Tested Protocol Variations**

| Assay Changes            | Average Log P <sub>e</sub> |                  |                  |                  |                  |                  |
|--------------------------|----------------------------|------------------|------------------|------------------|------------------|------------------|
|                          | Testosterone               | Propranolol      | Carbamazepine    | Warfarin         | Furosemide       | Methotrexate     |
| <b>Standard Protocol</b> | <b>-4.9 ±0.1</b>           | <b>-5.0 ±0.0</b> | <b>-5.2 ±0.0</b> | <b>-6.0 ±0.0</b> | <b>-6.8 ±0.1</b> | <b>-7.9 ±0.4</b> |
| 3 µL of 1% Lecithin      | -4.5 ±0.1                  | -5.1 ±0.0        | -5.3 ±0.1        | -5.9 ±0.0        | -6.8 ±0.0        | -7.8 ±0.1        |
| 5 µL of 1% Lecithin      | -4.7 ±0.1                  | -5.1 ±0.0        | -5.3 ±0.0        | -5.9 ±0.0        | -6.8 ±0.0        | -7.9 ±0.3        |
| 7 µL of 1% Lecithin      | -4.6 ±0.1                  | -5.1 ±0.0        | -5.3 ±0.0        | -5.9 ±0.1        | -6.8 ±0.0        | -7.6 ±0.4        |
| 5 µL of Methanol         | -4.9 ±0.0                  | -4.7 ±0.0        | -4.7 ±0.1        | -4.6 ±0.1        | -4.6 ±0.1        | -4.8 ±0.1        |
| 5 µL of Dodecane only    | -4.9 ±0.1                  | -5.2 ±0.1        | -5.3 ±0.0        | -6.0 ±0.0        | -6.7 ±0.0        | -7.7 ±0.2        |
| 5 µL of 2% Lecithin      | -5.1 ±0.1                  | -5.4 ±0.4        | -5.3 ±0.1        | -5.9 ±0.0        | -6.7 ±0.1        | -7.5 ±0.2        |
| 5 µL of 4% Lecithin      | -5.2 ±0.1                  | -5.2 ±0.0        | -5.3 ±0.0        | -5.9 ±0.0        | -6.7 ±0.1        | -7.4 ±0.1        |
| Immediate addition       | -4.9 ±0.0                  | -5.1 ±0.0        | -5.2 ±0.1        | -5.9 ±0.0        | -6.7 ±0.1        | -7.6 ±0.1        |
| 1 Minute                 | -4.9 ±0.0                  | -5.1 ±0.0        | -5.2 ±0.1        | -5.9 ±0.0        | -6.6 ±0.0        | -7.7 ±0.1        |
| 10 Minutes               | -4.9 ±0.0                  | -5.1 ±0.0        | -5.3 ±0.1        | -5.9 ±0.0        | -6.6 ±0.1        | -7.8 ±0.2        |
| 1 Hour                   | -4.9 ±0.0                  | -5.1 ±0.0        | -5.3 ±0.1        | -6.0 ±0.0        | -6.6 ±0.1        | -7.9 ±0.1        |



**Table 7:** Effects of Lecithin Concentration

| (n=6)                    |                                            |
|--------------------------|--------------------------------------------|
| Assay Changes            | Average Log P <sub>e</sub><br>Testosterone |
| 5 $\mu$ L of Methanol    | -4.9 $\pm$ 0.0                             |
| 5 $\mu$ L of Dodecane    | -4.9 $\pm$ 0.0                             |
| 5 $\mu$ L of 2% Lecithin | -5.9 $\pm$ 0.0                             |
| 5 $\mu$ L of 4% Lecithin | -6.2 $\pm$ 0.1                             |

## Time Course Studies

Diffusion of the tested compounds from the donor to acceptor compartments was monitored at various times over 48 hours. Drugs were added to successive rows of a Donor plate at a set time (48, 32, 28, 24, 8, 6, 4, 2 hrs) prior to (Donor/Acceptor) plate separation and analysis by UV/Vis. Each row of the plate had 2 replicates for each of the 6 drugs and three plates

were assayed resulting in a total of 6 replicates of each drug per time point. The ratio of the OD of the donor replicates to the OD of the initial Donor solution is plotted in **Figure 3** for the Donor plates. The ratio of the OD of acceptor replicates to the OD of the Equilibrium solution is plotted in **Figure 4** for the Acceptor plates. The log P<sub>e</sub> calculated for each time point is listed in **Table 8**.

**Figure 3:** Ratio of OD Donor/OD Initial Donor**Figure 4:** Ratio of OD Acceptor/OD Equilibrium**Table 8:** Average Log P<sub>e</sub> for Different Incubation Times

| Time (hrs.) | Average Log P <sub>e</sub> |             |               |          |            |              |
|-------------|----------------------------|-------------|---------------|----------|------------|--------------|
|             | Testosterone               | Propranolol | Carbamazepine | Warfarin | Furosemide | Methotrexate |
| 2           | -4.5                       | -4.9        | -5.2          | -5.9     | -5.9       | -6.6         |
| 4           | -4.6                       | -4.9        | -5.2          | -5.9     | -6.2       | -7.0         |
| 6           | -4.6                       | -4.9        | -5.2          | -5.9     | -6.4       | -7.2         |
| 8           | -4.7                       | -5.0        | -5.2          | -6.0     | -6.5       | -7.4         |
| 24          | -5.0                       | -5.1        | -5.2          | -6.0     | -7.0       | -7.8         |
| 28          | -5.0                       | -5.1        | -5.2          | -5.9     | -7.2       | -7.7         |
| 32          | -5.1                       | -5.1        | -5.2          | -6.0     | -7.2       | -7.8         |
| 48          | -5.0                       | -5.3        | -5.2          | -6.0     | -7.5       | -7.9         |

## Discussion

The permeability of the 7 drugs was determined using a donor concentration of 500  $\mu\text{M}$ . For testosterone and phenazopyridine, the donor concentration was reduced to 100  $\mu\text{M}$  after initial testing revealed their marginal solubility at the higher concentration. Overall, there were no significant ( $<0.2$  log units) variations due to well-to-well, plate-to-plate, day-to-day and lot-to-lot changes for the medium and high permeability drugs. Log  $P_e$  values obtained for the lower permeability drugs, furosemide and methotrexate, were more variable than those obtained for the other drugs due to analytical imprecision associated with being at or near the LOQ (using the standard, 12 to 16 hour incubation period).

In addition to testing assay reproducibility, several small protocol changes were tested to determine the effect that typical protocol variability might have on the calculated log  $P_e$ . Tables of the tested protocol changes can be found in the results section (**Tables 6 & 7**). By and large, the impact of any of these protocol modifications is quite small and does not result in any change in the rank ordering of compound permeability within the test panel of six drugs.

The composition of the lipid artificial membrane for the experiments described was 1% L- $\alpha$ -phosphatidylcholine (lecithin) in dodecane. The lecithin concentration was chosen from the lower end of the range of described literature values primarily for the sake of simplicity. A lipid artificial membrane of 1% lecithin in dodecane is likely not appropriate for accurate permeability ranking of all drug classes. For a particular target barrier, it is critical to choose the appropriate lipid mixture and lipid concentration to ensure accurate permeability ranking and correlation with human absorption data. Screening a large, diverse panel of commercially available compounds provides valuable information to aid in the selection of the appropriate lipid membrane constituents. For example, changes in the applied amount of lecithin solution or the concentration of the lecithin resulted in little or no change in the observed permeability rates of the test panel of six drugs (**Table 6**). However, when phenazopyridine was tested under some of the same conditions, there were significant changes in its observed permeability rates (**Table 7**).

A 48-hour time course experiment was performed to monitor the concentration changes of the donor and acceptor compartments for all six drugs. Graphs of the OD readings for each drug can be seen in the results section (See **Figures 3 & 4**). This type of experiment is useful for determining the appropriate length of transport time to achieve reproducible results. The calculated log  $P_e$  for high and medium permeable drugs varied  $\leq 0.4$  log between time points, whereas significant change was observed over time with low permeability compounds.

The fact that the log  $P_e$  calculated for each point does not change significantly for high and medium permeable drugs over 4–48 hours is an indication of the robustness of the equation.

As with any assay, there is an initial learning curve and periods of trial and error before reproducible results are obtained. Experience and familiarity with an assay help in spotting potential problems and making adjustments accordingly. Some potential pitfalls are not obvious, such as a drug's ability to be assayed by UV/Vis spectroscopy. Many drugs are not good UV/Vis chromophores so the proper analytical techniques must be chosen accordingly. Refer to **Table 1** for limits of detection determined from the standard curves of the six drugs assayed. Carbamazepine, for example, exhibits a comparatively high limit of detection by UV/Vis; however, due to its relatively high permeability, sufficient quantities are present in the acceptor compartment to permit the use of this detection method. Methotrexate, on the other hand, is a good UV/Vis chromophore and exhibits a much lower limit of detection. Due to its slow permeability rate, however, very little compound is present in the acceptor volume to be measured. Consequently, greater variability in the calculated log  $P_e$  of methotrexate is observed. A more sensitive detection method should be used for methotrexate (i.e., LC/MS).

Another significant source of method error may be related to compound solubility. Initial attempts to measure testosterone permeability were conducted using a donor solution concentration of 500  $\mu\text{M}$ —a concentration at which testosterone is only marginally soluble. This resulted in the drug partitioning onto the plate and membrane surfaces—thereby rendering accurate log  $P_e$  calculations impossible.

## Conclusions

The PAMPA assay is a robust and reproducible assay for determining passive, transcellular compound permeability. PAMPA is automation compatible, relatively fast (4–16 hours), inexpensive and straightforward. The majority of drugs ( $>80\%$ ) enter the bloodstream by passive diffusion through the intestinal epithelium. Consequently, permeability assays, such as PAMPA, that measure passive transport through lipophilic barriers correlate with human drug absorption values from published methods. The PAMPA assay provides the benefits of a biologically relevant membrane and the ability to tailor the membrane to a specific target such as the blood–brain barrier. Optimization of the incubation time, lipid mixture and lipid concentration will also enhance the assay's ability to mimic the target barrier.

## References

1. Kansy, M.; Senner, F.; Gubernator, K. Physicochemical High Throughput Screening: Parallel Artificial Membrane Permeation Assay in the Description of Passive Absorption Processes, *J. Med. Chem.*, 1998; 41, p. 1007–1010.
2. Kansy, M.; Fischer, H.; Kratzat, K.; Senner, F.; Wagner, B.; Parrilla, I. High-Throughput Artificial Membrane Permeability Studies in Early Lead Discovery and Development, *Pharmacokinetic Optimization in Drug Research*, 2001; XII, p. 448–464.
3. Wohnsland, F.; Faller, B. High-throughput Permeability pH Profile and High-throughput Alkane/Water Log P With Artificial Membranes, *J. Med. Chem.*, 2001; 44, p. 923–930.
4. Sugano, K.; Hamada, H.; Machida, M.; Ushio, H. High Throughput Prediction of Oral Absorption: Improvement of the Composition of the Lipid Solution Used in Parallel Artificial Membrane Permeation Assay, *J. Biomolecular Screening*, 2001; 6, p. 189–196.

## Ordering Information

| Description                                          | Qty/Pk | Cat. No.         |
|------------------------------------------------------|--------|------------------|
| <b>MultiScreen®-IP filter plate for PAMPA assays</b> |        |                  |
| with underdrain                                      | 50     | <b>MAIPN4550</b> |
| w/o underdrain                                       | 10     | <b>MAIPNTR10</b> |

## Accessories

| Description                           | Qty/Pk | Cat. No.         |
|---------------------------------------|--------|------------------|
| MultiScreen® transport receiver plate | 50     | <b>MATRNPS50</b> |

## Custom MultiScreen® Filter Plates

In need of customized plates? We'll create the perfect plate for your assay, with a combination of filter membrane, housing material and other required specifications.



For more information about MultiScreen® filter plates, please visit: [SigmaAldrich.com/multiscreen](https://SigmaAldrich.com/multiscreen)



To place an order or receive technical assistance:  
[SigmaAldrich.com/support](https://SigmaAldrich.com/support)



For local contact information:  
[SigmaAldrich.com/offices](https://SigmaAldrich.com/offices)

MilliporeSigma  
400 Summit Drive  
Burlington, MA 01803  
[SigmaAldrich.com](https://SigmaAldrich.com)

We have built a unique collection of life science brands with unrivalled experience in supporting your scientific advancements.

**Millipore® Sigma-Aldrich®**

© 2026 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. MilliporeSigma, the vibrant M, Millipore, Sigma-Aldrich, Supelco, and MultiScreen are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

MS\_AN1728ENEU Ver. 2.0 69002 04/2026

